Glimepiride

CHEMBL1481 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
490.6 g/mol
LogP
3.9
Phase
4

A sulfonylurea oral antidiabetic used to improve blood sugar control in type 2 diabetes by stimulating insulin release from the pancreas and enhancing insulin's action in peripheral tissues. It is often used alone or in combination with insulin or other diabetes medications when lifestyle modifications are insufficient. Regular monitoring of blood glucose is important to avoid hypoglycemia.

น้ำหนักโมเลกุล

490.6000 g/mol

LogP

3.90

TPSA

133.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O

InChI

InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

Molecular Formula

C24H34N4O5S

HBD / HBA

3 / 5

พันธะที่หมุนได้

7

อะตอมหนัก

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A sulfonylurea oral antidiabetic used to improve blood sugar control in type 2 diabetes by stimulating insulin release from the pancreas and enhancing insulin's action in peripheral tissues. It is often used alone or in combination with insulin or other diabetes medications when lifestyle modifications are insufficient. Regular monitoring of blood glucose is important to avoid hypoglycemia.

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Yes, Glimepiride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1481. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3476. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.